The Melanocortin System Explained: Five Receptors, Five Different Jobs
One signalling family governs skin pigment, appetite, sexual arousal, inflammation and stress hormones. Which receptor a compound binds is the whole story.
Five Receptors, Five Jobs
The melanocortin system runs on five receptors, and they do strikingly unrelated things. MC1R governs skin and hair pigmentation. MC2R handles the adrenal stress response. MC3R and MC4R sit largely in the brain and influence appetite, energy balance and sexual arousal. MC5R is involved in exocrine function, including sebaceous glands.
Why one family covers such different ground, in plain language: it looks arbitrary until you consider what the system originally coordinated. Pigmentation, appetite, stress response and reproductive behaviour are all things an animal needs to adjust together in response to its environment — the seasons, food availability, sunlight. What appears to be five unrelated jobs is really one ancient control panel for adapting to conditions. Evolution rarely builds separate systems when one will do.
Why Selectivity Is The Whole Story
Because the receptors do such different things, which one a compound binds determines what it does — and determines its regulatory fate.
Melanotan 1 is MC1R-selective, acting on pigmentation. It was developed into afamelanotide and holds FDA, EMA and TGA approval for a rare photosensitivity disorder.
PT-141 acts chiefly at MC4R and was approved as bremelanotide in 2019, the first compound to approach sexual function research through central neural pathways rather than vascular ones.
Melanotan 2 binds across the whole family. It is the parent structure PT-141 was derived from, and it holds no approval anywhere — precisely because a compound acting on five receptors at once is difficult to characterise for any single indication.
The pattern is consistent: the two compounds that were narrowed to one receptor became approved medicines; the one that was not remained a research compound.
Frequently Asked Questions
Compiled by the Southern Pacific Labs research team. Last updated July 2026.
Published References
- Cone RD. “Studies on the physiological functions of the melanocortin system.” Endocrine reviews, 2006. PubMed
- Langendonk JG, Balwani M, Anderson KE, et al. “Afamelanotide for Erythropoietic Protoporphyria.” The New England journal of medicine, 2015. PubMed
- Kingsberg SA, Clayton AH, Portman D, et al. “Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.” Obstetrics and gynecology, 2019. PubMed
- Molinoff PB, Shadiack AM, Earle D, et al. “PT-141: a melanocortin agonist for the treatment of sexual dysfunction.” Annals of the New York Academy of Sciences, 2003. PubMed
Related Research Guides
More in Melanocortin Research
The head-to-head guide — selectivity is the whole story.
Read guide →FDA-Approved MelanocortinThe MC4R-focused compound approved as Vyleesi.
Read guide →Selective MC1R AgonistThe MC1R-selective compound approved as afamelanotide.
Read guide →